FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#1 | ||
|
|||
Member
|
Results of the NILO-PD (Northwestern University) phase 2 trial of Nilotinib show the drug to be safe & tolerable. Unfortunately, it did not demonstrate any benefit for Parkinson's symptoms or biological measures. Basically, it doesn't have very good BBB penetration. Trials will begin on several other c-Abl inhibitors which appear to have better brain penetration.
There will be a webinar on Dec. 17th where more detail will be provided and questions answered. Though safe, nilotinib does not show promise for benefit for Parkinson's disease |
||
![]() |
![]() |
|
|
![]() |
||||
Thread | Forum | |||
New pharmacokinetics and biomarker data from the Georgetown Nilotinib trial | Parkinson's Disease | |||
Nilotinib in Parkinson's Disease (NILO-PD) | Parkinson's Disease | |||
Georgetown Receives FDA Clearance for Trial with Nilotinib in Alzheim | Parkinson's Disease | |||
Nilotinib Parkinson Trial to begin this summer! | Parkinson's Disease | |||
Six month follow up on Nilotinib trial. | Parkinson's Disease |